Icosavax, Inc.

Sanofi Ventures Secures $625 Million to Accelerate Biotech and Digital Health Investments

- Sanofi commits an additional $625 million to its corporate venture arm, bringing total assets under management to over $1.4 billion for strategic biotech investments. - The fund focuses on immunology, rare diseases, neurology, and vaccines while backing companies across all development stages from seed to crossover financing. - Sanofi Ventures achieved three successful exits in 2024 with combined acquisition value of $3.25 billion, demonstrating strong investment performance. - The expanded funding positions Sanofi to lead investment rounds during challenging market conditions when traditional venture capital deployment has slowed.